An 18 Percent Solution? Lilly And Daiichi Bet On A Premium Price For Effient Over Plavix

Wall Street analysts fret over a black box warning and see a slow uptake for Effient, but still expect drug to reach blockbuster status.

More from Archive

More from Pink Sheet